CHOSA ONCOLOGY AB
NNGM:CHOSA0.50
SEK
+0.00
(+0.81%)
ISIN
SE0007784319
Return %
Stock
S&P 500
1Y
-60.00
14.20
3Y
-24.87
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Peter Buhl Jensen
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Lund Sweden
- IPO Date
- Mar 9, 2016
- Website
- chosaoncology.com
- Similar Companies
- Business
- CHOSA ONCOLOGY AB is a clinical-stage biotechnology company that discovers, develops, and commercializes targeted oncology therapeutics and precision medicine companion diagnostics for the treatment of various cancer indications. Founded in 2007 and headquartered in Lund, Sweden, with research and operational activities in Denmark, the company focuses on combining tumor-targeted chemotherapy formulations with validated biomarker platforms to improve therapeutic efficacy and patient outcomes. The company's core product offerings and technology platforms include: LiPlaCis, an intravenous liposomal formulation of cisplatin engineered to selectively release active chemotherapeutic agents within tumor microenvironments through degradation by tumor-associated secretory phospholipase A2 enzymes; DRP-LiPlaCis, a proprietary multi-gene Drug Response Predictor companion diagnostic platform utilized to analyze patient biopsy expression profiles and identify individuals most likely to respond to LiPlaCis therapy; Clinical Oncology Candidates, consisting of targeted therapeutic programs undergoing clinical evaluation for the treatment of metastatic breast cancer, lung cancer, and other advanced solid malignancies; and Translational Biomarker Platforms, comprising molecular diagnostic screening, patient stratification methodologies, and clinical data analytics for targeted oncology regimens. Recent operational and strategic changes include the completion of a reverse takeover of Danish biotechnology company Chosa ApS by legacy entity RhoVac AB, resulting in the corporate rebranding to Chosa Oncology AB and the listing of its shares on the Nordic Growth Market SME exchange. Additionally, the company pivoted its strategic pipeline focus exclusively toward the LiPlaCis and DRP precision oncology platform under worldwide licensing agreements with Allarity Therapeutics, evaluated Phase 2b clinical efficacy data in biomarker-selected metastatic breast cancer patient populations, executed capital increases through rights issues to support operational development, and initiated strategic partnering discussions to support subsequent registration-stage clinical trials.